Value of intravenous thrombolysis in endovascular treatment for large-vessel anterior circulation stroke : individual participant data meta-analysis of six randomised trials
Copyright © 2023 Elsevier Ltd. All rights reserved..
BACKGROUND: Intravenous thrombolysis is recommended before endovascular treatment, but its value has been questioned in patients who are admitted directly to centres capable of endovascular treatment. Existing randomised controlled trials have indicated non-inferiority of endovascular treatment alone or have been statistically inconclusive. We formed the Improving Reperfusion Strategies in Acute Ischaemic Stroke collaboration to assess non-inferiority of endovascular treatment alone versus intravenous thrombolysis plus endovascular treatment.
METHODS: We conducted a systematic review and individual participant data meta-analysis to establish non-inferiority of endovascular treatment alone versus intravenous thrombolysis plus endovascular treatment. We searched PubMed and MEDLINE with the terms "stroke", "endovascular treatment", "intravenous thrombolysis", and synonyms for articles published from database inception to March 9, 2023. We included randomised controlled trials on the topic of interest, without language restrictions. Authors of the identified trials agreed to take part, and individual participant data were provided by the principal investigators of the respective trials and collated centrally by the collaborators. Our primary outcome was the 90-day modified Rankin Scale (mRS) score. Non-inferiority of endovascular treatment alone was assessed using a lower boundary of 0·82 for the 95% CI around the adjusted common odds ratio (acOR) for shift towards improved outcome (analogous to 5% absolute difference in functional independence) with ordinal regression. We used mixed-effects models for all analyses. This study is registered with PROSPERO, CRD42023411986.
FINDINGS: We identified 1081 studies, and six studies (n=2313; 1153 participants randomly assigned to receive endovascular treatment alone and 1160 randomly assigned to receive intravenous thrombolysis and endovascular treatment) were eligible for analysis. The risk of bias of the included studies was low to moderate. Variability between studies was small, and mainly related to the choice and dose of the thrombolytic drug and country of execution. The median mRS score at 90 days was 3 (IQR 1-5) for participants who received endovascular treatment alone and 2 (1-4) for participants who received intravenous thrombolysis plus endovascular treatment (acOR 0·89, 95% CI 0·76-1·04). Any intracranial haemorrhage (0·82, 0·68-0·99) occurred less frequently with endovascular treatment alone than with intravenous thrombolysis plus endovascular treatment. Symptomatic intracranial haemorrhage and mortality rates did not differ significantly.
INTERPRETATION: We did not establish non-inferiority of endovascular treatment alone compared with intravenous thrombolysis plus endovascular treatment in patients presenting directly at endovascular treatment centres. Further research could focus on cost-effectiveness analysis and on individualised decisions when patient characteristics, medication shortages, or delays are expected to offset a potential benefit of administering intravenous thrombolysis before endovascular treatment.
FUNDING: Stryker and Amsterdam University Medical Centers, University of Amsterdam.
| Errataetall: |
CommentIn: Lancet. 2023 Sep 16;402(10406):938-939. - PMID 37640036 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:402 |
|---|---|
| Enthalten in: |
Lancet (London, England) - 402(2023), 10406 vom: 16. Sept., Seite 965-974 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Majoie, Charles B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 18.09.2023 Date Revised 19.09.2023 published: Print-Electronic CommentIn: Lancet. 2023 Sep 16;402(10406):938-939. - PMID 37640036 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S0140-6736(23)01142-X |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361381352 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361381352 | ||
| 003 | DE-627 | ||
| 005 | 20231226085022.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S0140-6736(23)01142-X |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361381352 | ||
| 035 | |a (NLM)37640037 | ||
| 035 | |a (PII)S0140-6736(23)01142-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Majoie, Charles B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Value of intravenous thrombolysis in endovascular treatment for large-vessel anterior circulation stroke |b individual participant data meta-analysis of six randomised trials |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.09.2023 | ||
| 500 | |a Date Revised 19.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Lancet. 2023 Sep 16;402(10406):938-939. - PMID 37640036 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Intravenous thrombolysis is recommended before endovascular treatment, but its value has been questioned in patients who are admitted directly to centres capable of endovascular treatment. Existing randomised controlled trials have indicated non-inferiority of endovascular treatment alone or have been statistically inconclusive. We formed the Improving Reperfusion Strategies in Acute Ischaemic Stroke collaboration to assess non-inferiority of endovascular treatment alone versus intravenous thrombolysis plus endovascular treatment | ||
| 520 | |a METHODS: We conducted a systematic review and individual participant data meta-analysis to establish non-inferiority of endovascular treatment alone versus intravenous thrombolysis plus endovascular treatment. We searched PubMed and MEDLINE with the terms "stroke", "endovascular treatment", "intravenous thrombolysis", and synonyms for articles published from database inception to March 9, 2023. We included randomised controlled trials on the topic of interest, without language restrictions. Authors of the identified trials agreed to take part, and individual participant data were provided by the principal investigators of the respective trials and collated centrally by the collaborators. Our primary outcome was the 90-day modified Rankin Scale (mRS) score. Non-inferiority of endovascular treatment alone was assessed using a lower boundary of 0·82 for the 95% CI around the adjusted common odds ratio (acOR) for shift towards improved outcome (analogous to 5% absolute difference in functional independence) with ordinal regression. We used mixed-effects models for all analyses. This study is registered with PROSPERO, CRD42023411986 | ||
| 520 | |a FINDINGS: We identified 1081 studies, and six studies (n=2313; 1153 participants randomly assigned to receive endovascular treatment alone and 1160 randomly assigned to receive intravenous thrombolysis and endovascular treatment) were eligible for analysis. The risk of bias of the included studies was low to moderate. Variability between studies was small, and mainly related to the choice and dose of the thrombolytic drug and country of execution. The median mRS score at 90 days was 3 (IQR 1-5) for participants who received endovascular treatment alone and 2 (1-4) for participants who received intravenous thrombolysis plus endovascular treatment (acOR 0·89, 95% CI 0·76-1·04). Any intracranial haemorrhage (0·82, 0·68-0·99) occurred less frequently with endovascular treatment alone than with intravenous thrombolysis plus endovascular treatment. Symptomatic intracranial haemorrhage and mortality rates did not differ significantly | ||
| 520 | |a INTERPRETATION: We did not establish non-inferiority of endovascular treatment alone compared with intravenous thrombolysis plus endovascular treatment in patients presenting directly at endovascular treatment centres. Further research could focus on cost-effectiveness analysis and on individualised decisions when patient characteristics, medication shortages, or delays are expected to offset a potential benefit of administering intravenous thrombolysis before endovascular treatment | ||
| 520 | |a FUNDING: Stryker and Amsterdam University Medical Centers, University of Amsterdam | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Cavalcante, Fabiano |e verfasserin |4 aut | |
| 700 | 1 | |a Gralla, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Pengfei |e verfasserin |4 aut | |
| 700 | 1 | |a Kaesmacher, Johannes |e verfasserin |4 aut | |
| 700 | 1 | |a Treurniet, Kilian M |e verfasserin |4 aut | |
| 700 | 1 | |a Kappelhof, Manon |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Kentaro |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yongwei |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Fengli |e verfasserin |4 aut | |
| 700 | 1 | |a Morimoto, Masafumi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Miao, Zhongrong |e verfasserin |4 aut | |
| 700 | 1 | |a Rinkel, Leon A |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Jiacheng |e verfasserin |4 aut | |
| 700 | 1 | |a Otsuka, Toshiaki |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Shouchun |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Cognard, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Coutinho, Jonathan M |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Jiaxing |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Wenhuo |e verfasserin |4 aut | |
| 700 | 1 | |a Emmer, Bart J |e verfasserin |4 aut | |
| 700 | 1 | |a Eker, Omer |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Liyong |e verfasserin |4 aut | |
| 700 | 1 | |a Dobrocky, Tomas |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Huy-Thang |e verfasserin |4 aut | |
| 700 | 1 | |a Bush, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Ya |e verfasserin |4 aut | |
| 700 | 1 | |a LeCouffe, Natalie E |e verfasserin |4 aut | |
| 700 | 1 | |a Takeuchi, Masataka |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Hongxing |e verfasserin |4 aut | |
| 700 | 1 | |a Matsumaru, Yuji |e verfasserin |4 aut | |
| 700 | 1 | |a Strbian, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Lingsma, Hester F |e verfasserin |4 aut | |
| 700 | 1 | |a Nieboer, Daan |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Qingwu |e verfasserin |4 aut | |
| 700 | 1 | |a Meinel, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Mitchell, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Kimura, Kazumi |e verfasserin |4 aut | |
| 700 | 1 | |a Zi, Wenjie |e verfasserin |4 aut | |
| 700 | 1 | |a Nogueira, Raul G |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jianmin |e verfasserin |4 aut | |
| 700 | 1 | |a Roos, Yvo B |e verfasserin |4 aut | |
| 700 | 1 | |a Fischer, Urs |e verfasserin |4 aut | |
| 700 | 0 | |a IRIS collaborators |e verfasserin |4 aut | |
| 700 | 1 | |a Zi, Wenjie |e investigator |4 oth | |
| 700 | 1 | |a Nogueira, Raul |e investigator |4 oth | |
| 700 | 1 | |a Yang, Qingwu |e investigator |4 oth | |
| 700 | 1 | |a Liu, Jianmin |e investigator |4 oth | |
| 700 | 1 | |a Yang, Pengfei |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Yongwei |e investigator |4 oth | |
| 700 | 1 | |a Yan, Bernard |e investigator |4 oth | |
| 700 | 1 | |a Mitchell, Peter |e investigator |4 oth | |
| 700 | 1 | |a Miao, Zhong Rong |e investigator |4 oth | |
| 700 | 1 | |a Majoie, Charles B |e investigator |4 oth | |
| 700 | 1 | |a Roos, Yvo B |e investigator |4 oth | |
| 700 | 1 | |a Suzuki, Kentaro |e investigator |4 oth | |
| 700 | 1 | |a Kimura, Kazumi |e investigator |4 oth | |
| 700 | 1 | |a Matsumaru, Yuji |e investigator |4 oth | |
| 700 | 1 | |a Fischer, Urs |e investigator |4 oth | |
| 700 | 1 | |a Gralla, Jan |e investigator |4 oth | |
| 700 | 1 | |a Cavalcante, Fabiano W |e investigator |4 oth | |
| 700 | 1 | |a Kappelhof, Manon |e investigator |4 oth | |
| 700 | 1 | |a Treurniet, Kilian M |e investigator |4 oth | |
| 700 | 1 | |a Kaesmacher, Johannes |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Lei |e investigator |4 oth | |
| 700 | 1 | |a Bush, Steven |e investigator |4 oth | |
| 700 | 1 | |a Nieboer, Daan |e investigator |4 oth | |
| 700 | 1 | |a Lingsma, Hester F |e investigator |4 oth | |
| 700 | 1 | |a Rothwell, Peter |e investigator |4 oth | |
| 700 | 1 | |a Saver, Jeffrey |e investigator |4 oth | |
| 700 | 1 | |a Fiehler, Jens |e investigator |4 oth | |
| 700 | 1 | |a Li, Fengli |e investigator |4 oth | |
| 700 | 1 | |a Huang, Jiacheng |e investigator |4 oth | |
| 700 | 1 | |a Song, Jiaxing |e investigator |4 oth | |
| 700 | 1 | |a Hong, Bo |e investigator |4 oth | |
| 700 | 1 | |a Chen, Wenhuo |e investigator |4 oth | |
| 700 | 1 | |a Peng, Ya |e investigator |4 oth | |
| 700 | 1 | |a Han, Hongxing |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Liyong |e investigator |4 oth | |
| 700 | 1 | |a Li, Zifu |e investigator |4 oth | |
| 700 | 1 | |a Xing, Pengfei |e investigator |4 oth | |
| 700 | 1 | |a Shen, Hongjian |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Ping |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Xiaoxi |e investigator |4 oth | |
| 700 | 1 | |a Davis, Stephen |e investigator |4 oth | |
| 700 | 1 | |a Nguyen, Huy-Thang |e investigator |4 oth | |
| 700 | 1 | |a Donnan, Geoffrey |e investigator |4 oth | |
| 700 | 1 | |a Huo, Xiaochuan |e investigator |4 oth | |
| 700 | 1 | |a Nan, Guangxian |e investigator |4 oth | |
| 700 | 1 | |a Bivard, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Ma, Henry |e investigator |4 oth | |
| 700 | 1 | |a Vu, Dang Lu |e investigator |4 oth | |
| 700 | 1 | |a Campbell, Bruce |e investigator |4 oth | |
| 700 | 1 | |a Rinkel, Leon A |e investigator |4 oth | |
| 700 | 1 | |a Emmer, Bart J |e investigator |4 oth | |
| 700 | 1 | |a Coutinho, Jonathan M |e investigator |4 oth | |
| 700 | 1 | |a LeCouffe, Natalie E |e investigator |4 oth | |
| 700 | 1 | |a Dippel, Diederik W |e investigator |4 oth | |
| 700 | 1 | |a van der Lugt, Aad |e investigator |4 oth | |
| 700 | 1 | |a van Zwam, Wim H |e investigator |4 oth | |
| 700 | 1 | |a van Oostenbrugge, Robert J |e investigator |4 oth | |
| 700 | 1 | |a Uyttenboogaart, Maarten |e investigator |4 oth | |
| 700 | 1 | |a Costalat, Vincent |e investigator |4 oth | |
| 700 | 1 | |a Lycklama, Geert |e investigator |4 oth | |
| 700 | 1 | |a Hofmeijer, Jeannette |e investigator |4 oth | |
| 700 | 1 | |a van Norden, Anouk |e investigator |4 oth | |
| 700 | 1 | |a Otsuka, Toshiaki |e investigator |4 oth | |
| 700 | 1 | |a Takeuchi, Masataka |e investigator |4 oth | |
| 700 | 1 | |a Morimoto, Masafumi |e investigator |4 oth | |
| 700 | 1 | |a Kanazawa, Ryuzaburo |e investigator |4 oth | |
| 700 | 1 | |a Takayama, Yohei |e investigator |4 oth | |
| 700 | 1 | |a Kamiya, Yuki |e investigator |4 oth | |
| 700 | 1 | |a Shigeta, Keigo |e investigator |4 oth | |
| 700 | 1 | |a Okubo, Seiji |e investigator |4 oth | |
| 700 | 1 | |a Hayakawa, Mikito |e investigator |4 oth | |
| 700 | 1 | |a Strbian, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Eker, Omer |e investigator |4 oth | |
| 700 | 1 | |a Cognard, Christophe |e investigator |4 oth | |
| 700 | 1 | |a Meinel, Thomas |e investigator |4 oth | |
| 700 | 1 | |a Dobrocky, Tomas |e investigator |4 oth | |
| 700 | 1 | |a Jung, Simon |e investigator |4 oth | |
| 700 | 1 | |a Piechowiak, Eike |e investigator |4 oth | |
| 700 | 1 | |a Marnat, Gaultier |e investigator |4 oth | |
| 700 | 1 | |a Sibon, Igor |e investigator |4 oth | |
| 700 | 1 | |a Bourcier, Romain |e investigator |4 oth | |
| 700 | 1 | |a de Gaalon, Solene |e investigator |4 oth | |
| 700 | 1 | |a Papagiannaki, Chrysanthi |e investigator |4 oth | |
| 700 | 1 | |a Lefebvre, Margaux |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Lancet (London, England) |d 1945 |g 402(2023), 10406 vom: 16. Sept., Seite 965-974 |w (DE-627)NLM000473936 |x 1474-547X |7 nnns |
| 773 | 1 | 8 | |g volume:402 |g year:2023 |g number:10406 |g day:16 |g month:09 |g pages:965-974 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S0140-6736(23)01142-X |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 402 |j 2023 |e 10406 |b 16 |c 09 |h 965-974 | ||